Ju-Yoon Yoon

Ju-Yoon Yoon

Auto-generated profile, based on publicly available information

Ju-Yoon Yoon

Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department of Diagnostic Services, Shared Health Manitoba, Winnipeg, MB, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
JBJeffrey L Barr
Jeffrey L Barr
AKAllison Kruse
Allison Kruse
ARAnthony C. Restaino
Anthony C. Restaino
NTNatalia Tulina
Natalia Tulina
SSSarah Stuckelberger
Sarah Stuckelberger
PVPaola Vermeer
Paola Vermeer
Dense tumor innervation is associated with enhanced cancer progression and poor prognosis. We observed innervation in breast, prostate, pancreatic, lung, liver, ovarian, and colon cancers. Defining innervation in high-grade serous ovarian carcinoma (HGSOC) was a focus since sensory innervation was observed whereas the normal tissue contains predominantly sympathetic input. The origin, specific nerve type, and the mechanisms promoting innervation and driving nerve-cancer cell communications in ovarian cancer remain largely unknown. The technique of neuro-tracing enhances the study of tumor innervation by offering a means for identification and mapping of nerve sources that may directly and indirectly affect the tumor microenvironment. Here, we establish a murine model of HGSOC and utilize image-guided microinjections of retrograde neuro-tracer to label tumor-infiltrating peripheral neurons, mapping their source and circuitry. We show that regional sensory neurons innervate HGSOC tumors. Interestingly, the axons within the tumor trace back to local dorsal root ganglia as well as jugular–nodose ganglia. Further manipulations of these tumor projecting neurons may define the neuronal contributions in tumor growth, invasion, metastasis, and responses to therapeutics.

1 March 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
Yi-Wei TangYi-Wei Tang
Yi-Wei Tang
LLLorena Lozano
Lorena Lozano
XCXin Chen
Xin Chen
TQTroy D. Querec
Troy D. Querec
NKNora Katabi
Nora Katabi
KPKay J. Park
Kay J. Park

2 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJu-Yoon Yoon
Ju-Yoon Yoon
KSKeiyan Sy
Keiyan Sy
CBChristine Brezden-Masley
Christine Brezden-Masley
CSCatherine J Streutker
Catherine J Streutker
Gastric cancers comprise molecularly heterogeneous diseases; four molecular subtypes were identified in the cancer genome atlas (TCGA) study, with implications in patient management. In our efforts to devise a clinically feasible means of subtyping, we devised an algorithm based on histology and five stains available in most academic pathology laboratories. This algorithm was used to subtype our cohort of 107 gastric cancer patients from a single institution (St. Michael’s Hospital, Toronto, Canada), which was divided into 3 cases of EBV-positive, 23 of MSI, 27 of GS and 54 of CIN tumours. 87% of the tumours with diffuse histology were classified as GS subtype, which was notable for younger age. Examining for characteristic molecular features, aberrant p53 immunostaining was seen most frequently in the CIN subtype (43% in CIN vs. 6% in others), whereas ARID1A loss was rarely seen (6% vs. 35% in others). HER2 overexpression was seen exclusively in CIN tumours (17% of CIN tumours). PD-L1 positivity was seen predominantly in the EBV and MSI tumours. As with the TCGA study, no survival differences were seen between the subtypes. A similar strategy was employed to approximate the Asian Cancer Research Group (ACRG) molecular subtyping, with the addition of p53 IHC to the algorithm. We observed rates of ARID1A loss and HER2 overexpression that were comparable to the ACRG study. In summary, our algorithm allowed for clinically feasible means of subtyping gastric carcinoma that recapitulated the key molecular features reported in the large scale studies.

18 April 2022 in The Journal of Pathology
Verified
Journal Article
Closed access
JYJu Yoon Yoon
Ju Yoon Yoon
DCDavid B Chapel
David B Chapel
EGEmily Goebel
Emily Goebel
XQXiaohua Qian
Xiaohua Qian
JMJeffrey K Mito
Jeffrey K Mito
CCChristopher Crum
Christopher Crum

1 March 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
KTKelsie L. Thu
Kelsie L. Thu
JYJu-Yoon Yoon
Ju-Yoon Yoon
ATM —the gene at the moment in non-small cell lung cancer

7 August 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JYJu-Yoon Yoon
Ju-Yoon Yoon
JWJulia Y. Wang
Julia Y. Wang
MRMichael H. A. Roehrl
Michael H. A. Roehrl
Using unbiased proteomics, we had previously discovered that the catalytic proteasome subunit β type 7 (PSB7) protein is frequently overexpressed in colorectal adenocarcinomas. In this paper, we validate this finding and derive a prognostic significance for PSB7 by examining an expanded, well-annotated clinical cohort of 318 colorectal cancer patients. We found PSB7 protein levels to be similarly increased in both advanced stage primary disease and metastatic lesions. We then examined the prognostic value of PSB7 protein expression. Elevated PSB7 protein as well as PSMB7 mRNA levels showed associations with lower overall survival, particularly in female patients. The prognostic value of elevated PSB7 protein levels was highest for female patients who were older (>60 years of age at diagnosis) or who had received adjuvant chemotherapy. While high PSB7 did not retain its prognostic significance on multivariate analysis, we discuss the potential significance of PSB7 as a biomarker, considering its differential prognostic strength in different colorectal cancer patient groups and given its role as a subunit of the immunoproteasome for antigen presentation.